Tag Archives: pharmacology

¿Cuál es la mejor antiagregación en la angioplastia primaria a 12 meses?

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

 Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies.  Even though prolonged dual antiplatelet therapy (DAPT) might reduce the risk of important ischemic complications, this reduction will come at the expense of a significant increase of bleeding risk, which makes us reassess the cost benefit ratio of this decision. This is also why

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet therapy (DAPT) in 4579 patients treated with angioplasty and a biodegradable polymer sirolimus-eluting stent. This recent publication on the same study analyzed the evolution within the same strategies of the subgroup of patients with complex angioplasty and compared

SOLACI-CACI 2021 Virtual

SOLACI-CACI 2021 | DAPT Session

✔️ Watch again the DAPT Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 02:58 – Short versus long-term DAPT Therapy in High Risk Bleeding. Rationality and Preliminary Results of Master DAPT trial – Peter Smits. 31:20 – Rationality of long-term DAPT in Chronic Stable Angina – Ernesto Duronto. 48:14 – Selection of the best P2Y12

The most relevant articles in pharmacology in 2020

In this selection, we summarize for you the most important scientific news of 2020 in the field of pharmacology. 01- Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to the COLCOT trial, originally presented at the

Webinar SOLACI | Innovación terapia dual corta en pacientes con alto riesgo de sangrado

Watch again our Webinar on Short Dual Therapy in Patients with High Bleeding Risk

Watch again our Webinar on “Short Dual Therapy in Patients with High Bleeding Risk” on our Youtube account. The event was held on 12/08/2020 and had the participation of more than 200 people and the support of ABBOTT. What things will I learn if I watch this video? 04:02 | Innovation: Short Dual Therapy in

Los artículos más importantes de 2018 en farmacología / cardiología clínica - 2° parte

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology – Part 2

1- What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more    2- New European Hypertension Guidelines Contrast with American Recommendations The European